Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SC versus IV blinatumomab with HyperCVAD in newly diagnosed Ph-negative B-cell precursor ALL
jRCT2051250262Phase 3Not yet recruiting
- Sponsor
- Amgen
- Start
- Jun 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of blinatumomab in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Amgen. Primary endpoint: Overall Survival. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on jRCT2051250262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250262.